World's Best Scientists 2026 revealed!
Award Badge
Medicine
Israel
2026

D-Index & Metrics

Medicine

D-Index
110
Citations
44166
World Ranking
5568
National Ranking
12

Jacob M. Rowe publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jacob M. Rowe sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 605 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jacob M. Rowe D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jacob M. Rowe sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 110 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Israel Leader Award
  • 2025 - Research.com Medicine in Israel Leader Award

Overview

Jacob M. Rowe is affiliated with the Israel Ministry of Health in Israel. Their research focuses primarily on the field of medicine, with significant contributions across hematology, public health, environmental and occupational health, oncology, molecular biology, and genetics.

Their main topics of research include:

  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • CAR-T cell therapy research
  • Hematopoietic Stem Cell Transplantation
  • Childhood Cancer Survivors' Quality of Life
  • Multiple Myeloma Research and Treatments

Jacob M. Rowe has published extensively in several prominent scientific journals. Frequent publication venues include:

  • Blood
  • Haematologica
  • British Journal of Haematology
  • Leukemia & lymphoma/Leukemia and lymphoma
  • Best Practice & Research Clinical Haematology

Notable recent papers authored or co-authored by Rowe include:

  • "Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL", 2021, Blood
  • "Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial", 2022, Blood
  • "Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia", 2020, Nature Cancer
  • "Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia", 2022, Blood
  • "BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study", 2020, Cancer

Frequent collaborators of Jacob M. Rowe include:

  • Selina M. Luger
  • Mark R. Litzow
  • Elisabeth Paietta
  • Martin S. Tallman
  • Charles G. Mullighan

Best Publications

  • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

    Jay P. Patel;Mithat Gönen;Maria E. Figueroa;Hugo Fernandez

  • Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

    Marilyn L. Slovak;Kenneth J. Kopecky;Peter A. Cassileth;David H. Harrington

  • Anthracycline Dose Intensification in Acute Myeloid Leukemia

    Hugo F. Fernandez;Zhuoxin Sun;Xiaopan Yao;Mark R. Litzow

  • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

    Anthony H. Goldstone;Susan M. Richards;Hilliard M. Lazarus;Martin S. Tallman

  • Drug therapy for acute myeloid leukemia.

    Martin S. Tallman;Martin S. Tallman;Martin S. Tallman;D. Gary Gilliland;D. Gary Gilliland;D. Gary Gilliland;Jacob M. Rowe;Jacob M. Rowe;Jacob M. Rowe

  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

    Adele K. Fielding;Susan M. Richards;Rajesh Chopra;Hillard M. Lazarus

  • Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

    Jacob M. Rowe;Georgina Buck;Alan Kenneth Burnett;Raj Chopra

  • Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission

    Peter A. Cassileth;David P. Harrington;Frederick R. Appelbaum;Hillard M. Lazarus

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

    Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards

  • All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

    Martin S. Tallman;Janet W. Andersen;Charles A. Schiffer;Frederick R. Appelbaum

  • Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia

    Panagiotis Ntziachristos;Panagiotis Ntziachristos;Aristotelis Tsirigos;Pieter Van Vlierberghe;Jelena Nedjic

  • Acute promyelocytic leukemia: evolving therapeutic strategies

    Martin S. Tallman;Chadi Nabhan;James H. Feusner;Jacob M. Rowe

  • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

    Bayard L. Powell;Barry Moser;Wendy Stock;Robert E. Gallagher

  • PAX5 -driven subtypes of B-progenitor acute lymphoblastic leukemia

    Zhaohui Gu;Michelle L. Churchman;Kathryn G. Roberts;Ian Moore

  • Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

    Jae H. Park;Baozhen Qiao;Katherine S. Panageas;Maria J. Schymura

  • Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers

    Richard S. Maser;Bhudipa Choudhury;Peter J. Campbell;Bin Feng

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

  • T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

    David I. Marks;Elisabeth M. Paietta;Anthony V. Moorman;Susan M. Richards

  • ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

    JM Rowe;G Buck;AK Burnett;R Chopra

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia

    A Moorman;C J Harrison;Buck Gan.;S M Richards

Frequent Co-Authors

Martin S. Tallman
Martin S. Tallman Northwestern University
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Anthony H. Goldstone
Anthony H. Goldstone University College Hospital
Adolfo A. Ferrando
Adolfo A. Ferrando Columbia University
Gordon W. Dewald
Gordon W. Dewald Mayo Clinic
John M. Bennett
John M. Bennett University of Rochester Medical Center
Arnon Nagler
Arnon Nagler Sheba Medical Center
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in Medicine or a related health field in the USA, there are a variety of online degrees that can help you expand your options and gain new skills. Flexible and accredited programs make it easier to balance your studies with other responsibilities.

For those interested in health and wellness, nutrition degrees online offer science-based education in dietetics, food science, and preventive medicine. These programs can open doors to jobs in clinical dietetics, public health, or the food industry.

Aspiring healthcare leaders can pursue online mha programs designed to develop skills for management and administrative roles in hospitals, clinics, or health organizations.

Registered Nurses aiming for career advancement may find online rn to bsn programs without clinical requirements especially convenient, allowing them to earn a bachelor’s degree remotely and efficiently.

For those seeking the highest level of nursing practice, accelerated dnp programs online provide an accessible way to earn a Doctor of Nursing Practice and open up leadership or advanced clinical positions.

Best Scientists Citing Jacob M. Rowe

Trending Scientists

Recently Published Articles